Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes.
Previous reports have shown that glycosphingolipids can modulate the activity of the insulin receptor, and studies in transgenic mice suggest a link between altered levels of various gangliosides and the development of insulin resistance. Here, we show that an inhibitor of glycosphingolipid synthesis can improve glucose control and increase insulin sensitivity in two different diabetic animal models. In the Zucker diabetic fatty rat, the glucosylceramide synthase inhibitor (1R,2R)-nonanoic acid[2-(2',3'-dihydro-benzo [1, 4] dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]- amide-l-tartaric acid salt (Genz-123346) lowered glucose and A1C levels and improved glucose tolerance. Drug treatment also prevented the loss of pancreatic beta-cell function normally observed in the Zucker diabetic fatty rat and preserved the ability of the animals to secrete insulin. In the diet-induced obese mouse, treatment with Genz-123346 normalized A1C levels and improved glucose tolerance. Analysis of the phosphorylation state of the insulin receptor and downstream effectors showed increased insulin signaling in the muscles of the treated Zucker diabetic fatty rats and diet-induced obese mice. These results suggest that inhibiting glycosphingolipid synthesis can significantly improve insulin sensitivity and glucose homeostasis and may therefore represent a novel therapeutic approach for the treatment of type 2 diabetes.
Zhao
Hongmei
H
Genzyme, Framingham, MA 01701-9322, USA.
Przybylska
Malgorzata
M
Wu
I-Huan
IH
Zhang
Jinhua
J
Siegel
Craig
C
Komarnitsky
Svetlana
S
Yew
Nelson S
NS
Cheng
Seng H
SH
D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000503:physiopathology*; D004146:Dioxanes / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005963:Glucosylceramides / Q000378:metabolism*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006028:Glycosphingolipids / Q000096:biosynthesis*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood*; D008055:Lipids / Q000097:blood; D008099:Liver / Q000378:metabolism; D008297:Male; D009765:Obesity / Q000097:blood; D011759:Pyrrolidines / Q000627:therapeutic use*; D051381:Rats; D011924:Rats, Zucker
D001786:Blood Glucose; D004146:Dioxanes; D005963:Glucosylceramides; D006442:Glycated Hemoglobin; D006028:Glycosphingolipids; D007004:Hypoglycemic Agents; D007328:Insulin; D008055:Lipids; D011759:Pyrrolidines; C520404:(2-(2',3'-dihydrobenzo(1,4)dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethylethyl)nonanoic acid amide